Delhi High Court Backs Patent Office in Rejecting Diabetes Drug Application

The Delhi High Court has upheld the patent office's rejection of a patent application by Amylin Pharmaceuticals and AstraZeneca for their sustained-release diabetes injection.

The Court has upheld the Patent Office's refusal of a patent for their sustained-release exenatide injection for diabetes, ruling that the formulation was 'obvious' from existing science and lacked the inventive step required for protection.

The court found the invention lacked sufficient inventive step over existing prior art, maintaining India's strict patentability standards for pharmaceutical innovations.